Randomised comparative study of folfox6m plus SIR-Spheres microspheres versus folfox6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma

Primary objectives: The primary outcome of this study is progression free survival.
Primary endpoints: The primary outcome of this study is progression free survival.Progression-free survival (PFS) is defined as the time interval between randomisation and the date of tumour progression. Tumour progression in the liver is determined from serial CT scans. Diagnosis of tumour recurrence (progression of disease) should be made by using RECIST Criteria.The documented date of recurrence will be the date of confirmation of the recurrence. At the time of recurrence, the investigator should clearly indicate the site of tumour recurrence (hepatic or extra-hepatic).